At the upcoming Outsourcing in Clinical Trials (OCT) and Clinical Trial Supply (CTS) Korea 2025 meetings, which will take place 2–3 December 2025, leading professionals in clinical operations and supply chain leaders will gather to discuss South Korea’s position in the global clinical research landscape.
This year’s conferences will focus on key themes such as patient engagement, regulatory shifts and partnerships with sponsors, contract research organisations (CROs) and supply partners.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The meeting will start off with a presentation from Sol Han, Chief Medical Officer, Head of Clinical Development Center at the Seoul-based Cyrus Therapeutics, who will discuss the strategies for choosing the correct CRO by engaging them at the right stage, involving them in early protocol and trial planning, and fostering a collaborative partnership.
Developments in radiopharmaceuticals, an area rapidly gaining global traction, will also be highlighted in a session led by Novotech, showing how multi-country trial strategies are becoming increasingly important amidst shifting US Food and Drug Administration (FDA) expectations and Korea’s growing interest in the field.
The meeting will continue with a keynote speech from Kazuhiko Takahata, senior Director and head of Clinical Development Group 3 at Clinical Development Centre, at Kyowa Kirin, who will outline the company’s structured approach to incorporating patient feedback throughout the entire product lifecycle. The keynote will demonstrate how patient insight can directly influence protocol and device design.
The conference will then split off into two different meetings; one will cover Outsourcing and Clinical Operations while the other will focus on Clinical Trial Supply.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThroughout the day, parallel sessions will cover topics like adaptive supply chain strategies, the globalisation of Phase I research, (J)APAC regional supply considerations, patient access trends, big-data-driven oversight, requirements for multi-regional manufacturing and the strategic role of CROs in Asia.
The first day will end with two panel discussions; in the OCT meeting, a panel will explore how emerging technologies like artificial intelligence (AI), automation, and digital platforms, are reshaping clinical trials by boosting efficiency, and enabling innovative trial designs, featuring experts from GlobalData, Kyowa Kirin and Jeju Biotek. Simultaneously, the CTS meeting will end with a panel focusing on strengthening global clinical supply management through improved end-to-end collaboration, with transparent communication and aligned incentives between sponsors and vendors to prevent delays and improve supply reliability.
The second day at the OCT meeting will open with sessions on how AI-driven medical imaging is reshaping trial efficiency, followed by a keynote on implementing decentralised clinical trials (DCT) to expand patient access and improve recruitment. The keynote on the evolving role of DCTs will be delivered by a Novartis Taiwan representative and explore the considerations that determine whether a DCT model is appropriate for a study. Later, a panel will delve into how Korea’s rapidly evolving clinical trial ecosystem affects small and mid-sized biopharma, addressing growth trends, challenges in selecting and managing vendors and CROs, and recent regulatory shifts influencing trial approvals.
Running in parallel, a panel at the CTS meeting will tackle the most common causes of clinical supply disruptions, such as shipping delays, customs bottlenecks, and packaging failures, while highlighting gaps in global guidance and practical solutions to reinforce supply-chain resilience.
The OCT conference will then feature a session from a Hanmi Pharma director on FDA initiatives for accelerated approval pathways. The talk will cover updated expedited approval pathways, guidance on dose optimisation, expectations around surrogate endpoints and biomarker-driven designs, and how sponsors can align trial strategies to meet evolving FDA standards.
The whole meeting will conclude with interactive roundtables on long-term development planning and strengthening sponsor–CRO collaboration, followed by closing remarks.
The Outsourcing in Clinical Trials (OCT) and Clinical Trial Supply (CTS) Korea 2025 meetings are hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology.
Click here to read the agenda for the conference for Outsourcing in Clinical Trials (OCT) Korea 2025 and Clinical Trial Supply (CTS) Korea 2025.
